BCL2 and B-cell chronic lymphocytic leukemia: In patients with CLL, the most common recurrent mechanism of venetoclax resistance identified to date is the acquisition of a point mutation in the BCL2 gene, resulting in the substitution of a valine for glycine at position 101 of the BCL2 protein (G101V mutation) [105].